search
Back to results

The Effect of Chymosin on the Intestinal Absorption of Calcium (Chymosin)

Primary Purpose

Osteoporosis, Osteopenia

Status
Completed
Phase
Phase 1
Locations
Denmark
Study Type
Interventional
Intervention
Drug A Chymosin
Drug B: Placebo
Sponsored by
University of Aarhus
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Osteoporosis focused on measuring Chymosin, 24H urine calcium excretion, Calcium absorption, Intestinal Absorption of Calcium

Eligibility Criteria

25 Years - 40 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • A stable daily intake of calcium on estimated 500-1200 mg, of which dairy products are minimum 500 mg
  • Speak and read Danish.
  • Written consent after verbal and written information

Exclusion Criteria:

  • Known lactose intolerance / milk allergy
  • Use of calcium supplements in tablet or powder
  • Intake of vitamin D supplements exceeding 10 micro grams/day
  • A habitual dietary calcium intake exceeding 1200 mg/day
  • Impaired renal function (plasma creatinine >150 micro mol/L)
  • Impaired liver function (plasma ALT >200 U/L, alkaline phosphatase >400 U/L).
  • Previous or present malignancies(including metastases).
  • sarcoidosis or second granulomatous disease which has caused hypercalcaemia
  • Pregnancy, breastfeeding
  • Postmenopausal women
  • Disease or treatment with drugs known to affect calcium homeostasis, including diuretics, osteoporosis agents, lithium, steroids, etc..
  • Pledged due to chronic alcoholism.
  • Severe medical or social problems which makes it unlikely that the participant can complete the survey
  • Lack of willingness / desire to participate

Sites / Locations

  • Ward 900, Osteporosis clinic, Aarhus University Hospital, THG

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Drug A: Chymosin

Drug B: Placebo

Arm Description

A: 5 drops of Chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.

B: 5 drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.

Outcomes

Primary Outcome Measures

The effect of the intervention on the 24 hours urine excretion of calcium corrected for creatinine
The effect of the intervention on the 24 hours urine excretion of calcium corrected for creatinine

Secondary Outcome Measures

The effect of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels on the amount of calcium absorbed and the potential impact of chymosin
Vitamin D: The importance of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D on the amount of calcium absorbed and the potential impact of chymosin.
The immediate biological effects of the intervention on P-PTH, and bone turnover (P-osteocalcin, P-BSAP, U-NTX)
The immediate biological effects of the intervention on parathyroid function (PTH) and bone turnover (P-osteocalcin, plasma bone specific alkaline phosphatase, and the renal excretion of cross-linked N-terminal telopeptide of type 1 collagen (NTx/Cr) ratio).
Relations between bone mineral density (BMD) and the measured parameters (P-25OHD, P-1,25(OH)2D), P-PTH, P-osteocalcin, P-BSAP, U-NTx/Cr)
To explore relations between bone mineral density (BMD) and the measured parameters (P-25OHD, P-1,25(OH)2D), P-PTH, P-osteocalcin, P-BSAP, U-NTx/Cr).

Full Information

First Posted
April 27, 2011
Last Updated
March 20, 2012
Sponsor
University of Aarhus
search

1. Study Identification

Unique Protocol Identification Number
NCT01370941
Brief Title
The Effect of Chymosin on the Intestinal Absorption of Calcium
Acronym
Chymosin
Official Title
The Effect of Chymosin on the Intestinal Absorption of Calcium: A Randomized Controlled Cross-over Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2012
Overall Recruitment Status
Completed
Study Start Date
April 2011 (undefined)
Primary Completion Date
March 2012 (Actual)
Study Completion Date
March 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Aarhus

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
An adequate calcium intake is important for bone turnover and the risk of developing osteoporosis. Yet many studies have documented that supplementation with calcium tablets are often associated with a poor compliance, therefore it is important to explore ways to better calcium influx. Calcium consumed through dairy products must first be cleaved from the molecules which it is bound to before it can be absorbed. Chymosin is an enzyme which cleaves the protein binding between some amino acids in κ-casein. The reaction occurs after ingestion of milk and causes a process whereby the time the milk is staying gastrointestinal tract is extended, this can lead to enhanced uptake of calcium. When the body's calcium balance is in equilibrium excretion in urine (24 h) in roughly the size of the intake, whereby a measurement of circadian urine excretion of calcium can determine the amount of calcium absorbed from the intestine. The investigators want to clarify whether the addition of chymosin to milk increases calcium absorption. Secondary to explore issues of significance for this effect, including vitamin D status and amount of daily calcium intake and whether a change in calcium absorption has immediate effects on bone turnover (measured as plasma osteocalcin, bone specific alkaline phosphatase (BSAP), and the renal excretion of cross-linked N-terminal telopeptide of type 1 collagen (NTx/Cr) ratio) and on the parathyroid function (measured as PTH). Finally we will explore relations between bone mineral density (BMD) and the measured parameters (in terms of P-PTH, P-25OHD, P-1,25(OH)2D, P-osteocalcin, P-BSAP, and U-NTx/Cr).
Detailed Description
Background: Osteoporosis is a frequent disease. Allegedly, more than 500,000 Danes are diagnosed with osteoporosis and, in consequence, seems every year more than 20,000 fractures. A number of factors are known to increase the risk of osteoporosis, including a low daily intake of calcium. Several clinical trials with calcium supplements for adults (with or without simultaneous supplementation of vitamin D) have shown an increase in bone mineral density (Bone Mineral Density, BMD) and reduction the risk of fractures. Similarly, several studies have shown that high milk intake during childhood and adolescence may increase bone mass and reduce the risk of fractures later in life. Since an adequate calcium intake is important for bone turnover and the risk of developing osteoporosis, it is important to explore ways to better calcium influx. Several studies have documented that supplementation with calcium tablets are often associated with a poor compliance - people do not remember to take the tablets. It is therefore desirable to find methods that can increase the intake of the amount of calcium which occurs naturally in the diet. Calcium consumed through dairy products must first be cleaved from the molecules which it is bound to before it can be absorbed. Various methods have been tried to optimizing the amount of calcium absorbed from dairy products, including the addition of so called fructo-oligosaccharides (FOSS) and casein phosphopeptides (CPPs). Chymosin is an enzyme which cleaves the protein binding between some amino acids in κ-casein. The reaction occurs after ingestion of milk and causes a process whereby the time the milk is staying gastrointestinal tract is extended, this can lead to enhanced uptake of calcium. When the body's calcium balance is in balance the excretion in urine (24 h)is in roughly the size as the intake. Therefore a measurement of circadian urine excretion of calcium can determine the amount of calcium absorbed from the intestine. Purpose and hypothesis: Primarily the study intends to clarify whether the addition of chymosin to milk increases the intestinal calcium absorption. Secondary to explore issues of significance for this effect, including vitamin D status and amount of daily calcium intake, and whether a change in calcium absorption has immediate effects on bone turnover (measured as plasma osteocalcin, plasma bone specific alkaline phosphatase, and the renal excretion of cross-linked N-terminal telopeptide of type 1 collagen (NTx/Cr) ratio) and on the parathyroid function (measured as PTH). Finally we will explore relations between bone mineral density (BMD) and the measured parameters (in terms of P-PTH, P-25OHD, P-1,25(OH)2D, P-osteocalcin, P-BSAP, and U-NTx/Cr). Design: The study is conducted as a randomized double-blinded controlled cross-over trial in which 125 healthy subjects will be asked to drink a glass of milk with or without added chymosin at two occasions. The two time two test days will be separated by 10-18 days. Neither study participants nor the staff conducting the investigation (investigator) will while the trial will be conducted know on which day of the trial which milk contains chymosin (double-blinded). About chymosin added to milk on the first or second test day will be determined by lot (randomized study). Study Population: Healthy participants in the agegroup of 25-40 years old are recruited. From the central personal register (CPR register) a list of young people living in the Aarhus area is drawn up, followed by sending out a direct letter asking for participation in the study. At the same time a questionnaire will clarify whether participation is possible, i.e. whether the criteria for participation in the survey are meet.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoporosis, Osteopenia
Keywords
Chymosin, 24H urine calcium excretion, Calcium absorption, Intestinal Absorption of Calcium

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
125 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Drug A: Chymosin
Arm Type
Active Comparator
Arm Description
A: 5 drops of Chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
Arm Title
Drug B: Placebo
Arm Type
Placebo Comparator
Arm Description
B: 5 drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
Intervention Type
Dietary Supplement
Intervention Name(s)
Drug A Chymosin
Other Intervention Name(s)
Chy-max plus IMCU200
Intervention Description
Five drops of chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
Intervention Type
Dietary Supplement
Intervention Name(s)
Drug B: Placebo
Other Intervention Name(s)
Water
Intervention Description
B: Five drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
Primary Outcome Measure Information:
Title
The effect of the intervention on the 24 hours urine excretion of calcium corrected for creatinine
Description
The effect of the intervention on the 24 hours urine excretion of calcium corrected for creatinine
Time Frame
Two time two days over an eighteen days period
Secondary Outcome Measure Information:
Title
The effect of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels on the amount of calcium absorbed and the potential impact of chymosin
Description
Vitamin D: The importance of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D on the amount of calcium absorbed and the potential impact of chymosin.
Time Frame
Two time two days over an eighteen days period
Title
The immediate biological effects of the intervention on P-PTH, and bone turnover (P-osteocalcin, P-BSAP, U-NTX)
Description
The immediate biological effects of the intervention on parathyroid function (PTH) and bone turnover (P-osteocalcin, plasma bone specific alkaline phosphatase, and the renal excretion of cross-linked N-terminal telopeptide of type 1 collagen (NTx/Cr) ratio).
Time Frame
Two time two days over an eighteen days period
Title
Relations between bone mineral density (BMD) and the measured parameters (P-25OHD, P-1,25(OH)2D), P-PTH, P-osteocalcin, P-BSAP, U-NTx/Cr)
Description
To explore relations between bone mineral density (BMD) and the measured parameters (P-25OHD, P-1,25(OH)2D), P-PTH, P-osteocalcin, P-BSAP, U-NTx/Cr).
Time Frame
Will be measured one time at one of the two time two days over an eighteen days period

10. Eligibility

Sex
All
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: A stable daily intake of calcium on estimated 500-1200 mg, of which dairy products are minimum 500 mg Speak and read Danish. Written consent after verbal and written information Exclusion Criteria: Known lactose intolerance / milk allergy Use of calcium supplements in tablet or powder Intake of vitamin D supplements exceeding 10 micro grams/day A habitual dietary calcium intake exceeding 1200 mg/day Impaired renal function (plasma creatinine >150 micro mol/L) Impaired liver function (plasma ALT >200 U/L, alkaline phosphatase >400 U/L). Previous or present malignancies(including metastases). sarcoidosis or second granulomatous disease which has caused hypercalcaemia Pregnancy, breastfeeding Postmenopausal women Disease or treatment with drugs known to affect calcium homeostasis, including diuretics, osteoporosis agents, lithium, steroids, etc.. Pledged due to chronic alcoholism. Severe medical or social problems which makes it unlikely that the participant can complete the survey Lack of willingness / desire to participate
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Leif Mosekilde, Professor
Organizational Affiliation
Aarhus University Hospital, THG
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ward 900, Osteporosis clinic, Aarhus University Hospital, THG
City
Aarhus
State/Province
Jutland
ZIP/Postal Code
8000
Country
Denmark

12. IPD Sharing Statement

Citations:
PubMed Identifier
25515208
Citation
Moller UK, Jensen LT, Mosekilde L, Rejnmark L. Effects of adding chymosin to milk on calcium homeostasis: a randomized, double-blind, cross-over study. Calcif Tissue Int. 2015 Feb;96(2):105-12. doi: 10.1007/s00223-014-9942-8. Epub 2014 Dec 18.
Results Reference
derived

Learn more about this trial

The Effect of Chymosin on the Intestinal Absorption of Calcium

We'll reach out to this number within 24 hrs